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REVIEW
Fluid resuscitation in human sepsis: Time 
to rewrite history?
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Abstract 
Fluid resuscitation continues to be recommended as the first-line resuscitative therapy for all patients with severe 
sepsis and septic shock. The current acceptance of the therapy is based in part on long history and familiarity with 
its use in the resuscitation of other forms of shock, as well as on an incomplete and incorrect understanding of the 
pathophysiology of sepsis. Recently, the safety of intravenous fluids in patients with sepsis has been called into 
question with both prospective and observational data suggesting improved outcomes with less fluid or no fluid. 
The current evidence for the continued use of fluid resuscitation for sepsis remains contentious with no prospective 
evidence demonstrating benefit to fluid resuscitation as a therapy in isolation. This article reviews the historical and 
physiological rationale for the introduction of fluid resuscitation as treatment for sepsis and highlights a number of 
significant concerns based on current experimental and clinical evidence. The research agenda should focus on the 
development of hyperdynamic animal sepsis models which more closely mimic human sepsis and on experimental 
and clinical studies designed to evaluate minimal or no fluid strategies in the resuscitation phase of sepsis.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Sepsis is a significant global health problem. The world-
wide incidence of sepsis is increasing, with current esti-
mates between 20 and 30  million cases annually [1–5]. 
The mortality of septic shock, the most severe form of 
sepsis, continues to be higher than 50% [5, 6]. The cost 
associated with a single admission of a patient with sep-
sis has been estimated to be in excess of Euro 20,000 [7, 
8]. The treatment of sepsis has not significantly changed 
over the past 40 years, with the currently used therapies 
of antibiotics, source control, fluid resuscitation and judi-
cious use of vasopressors recommended in a familiar 
form in the literature as far back as 1970 [9].
Fluid resuscitation remains the most enduring of sepsis 
treatments predating even antibiotics. Its beginnings date 
to the European cholera epidemic of the 1830s, where it 
was first used to replace the losses associated with chol-
era diarrhoea [10]. In modern practice, fluid resuscitation 
has developed to encompass both corrections of absolute 
and relative hypovolemic states with the additional goal 
of augmenting cardiac output to restore organ perfusion 
pressure and improve oxygen transport to cells [5, 11, 
12].
Unfortunately, there is no agreed uniform definition of 
fluid resuscitation in the literature. Fluid administration 
is not necessarily the same as fluid resuscitation. It is 
important to differentiate between fluid substitution and 
volume substitution in intensive care patients, a distinc-
tion that has not always been appreciated sufficiently in 
the design of fluid studies [13]. For the sake of simplicity 
and consistency, we define fluid resuscitation for sepsis 
in this review as the administration of intravenous flu-
ids to correct sepsis-induced tissue hypoperfusion. This 
definition is consistent with the surviving sepsis guide-
lines and implies a targeted approach to a clinical prob-
lem [12].
The following article reviews the rationale for the intro-
duction of fluid resuscitation as treatment for sepsis and 
highlights a number of significant concerns based on cur-
rent experimental and clinical evidence.
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Evolution of fluid resuscitation as a therapy 
for septic shock
R. Hermann was a German chemist working in Mos-
cow during the second cholera pandemic in 1830. He 
proposed injecting water into the circulation to replace 
lost fluid after observing haemoconcentration in cholera 
patients. His clinician colleague Jaehnichen subsequently 
injected a cholera patient intravenously with 6  oz. of 
water, which resulted in a notable improvement in the 
patient’s pulse. However, the patient died 2  h later [14, 
15]. When the cholera pandemic arrived in England, in 
1831 O’Shaughnessy, on also demonstrating haemocon-
centration in cholera patients, recommended intravenous 
fluids to “restore blood to its natural specific gravity” and 
“restore its deficient saline matters” [16]. This leads to 
Latta’s first successful attempts at fluid resuscitation with 
crystalloid solutions [10, 14–16]. Despite these and other 
initial reports of success during the pandemic, the prac-
tice did not achieve widespread use [10].
Fluid resuscitation was re-discovered some 30  years 
later as a treatment for severe haemorrhage. In 1864, 
Goltz was the first to suggest that loss of intravascular 
volume rather than a loss of oxygen carrying capacity 
might be the central mechanism of death in haemor-
rhagic shock [17]. This was supported by the experiments 
of Konecker and Sander, who found that dogs who were 
haemorrhaged 50% of their blood volume could be suc-
cessfully resuscitated with a crystalloid solution [17]. 
Following these initial experiments, numerous clinical 
reports described the successful use of intravenous flu-
ids in cases of major surgical and obstetric haemorrhage. 
Fluid resuscitation then began to be recommended as a 
treatment for haemorrhage [18–22].
The development of a new paradigm for the condition 
“shock” accompanied the expansion of the use of intra-
venous fluids. Prior to the nineteenth century, “shock” 
remained a concept without a clear definition [23, 24]. 
It was recognised that many different insults could lead 
to this common terminal syndrome [23, 24]. Theories 
on pathogenesis were numerous and varied, and focused 
mainly around primary nervous system failure or exhaus-
tion of “vital energies” [23, 25]. Parallel developments 
in medical technology, such as the development of the 
sphygmomanometer in 1903, led to the ability to reliably 
and non-invasively measure blood pressure [24]. Experi-
ments by Crile and others showed that injuries such as 
trauma, manipulation of internal organs and electrocu-
tion were able to produce a syndrome of systemic hypo-
tension [25, 26]. On that basis, Mummery and Crile 
redefined shock as a condition with inadequate systemic 
blood pressure as its hallmark [24, 27]. Crile’s later exper-
iments demonstrated intravenous saline as one of the few 
therapies capable of improving blood pressure in shock 
[27, 28]. By the early 1900s, several articles appeared rec-
ommending fluid boluses as an effective therapy for the 
undifferentiated syndrome of “shock” [29, 30].
The ability to measure cardiac output fundamentally 
changed the paradigm of shock again. The increased 
understanding of circulatory pathophysiology allowed 
the differentiation and description of shock by Blalock 
into the different subtypes recognisable today [31]. The 
subtype of vasodilatory shock (vasogenic in the origi-
nal article) accounts for the dominant phenotype seen 
in human septic shock and endotoxemia [9, 32–35]. The 
ability to measure cardiac output led to the observation 
of an association between the development of a hyper-
dynamic circulation and survival in both experimental 
models and clinical septic shock [35–37]. This compelling 
finding along with the increased lactate and oliguria of 
sepsis was interpreted as evidence of potentially revers-
ible tissue hypoperfusion [35–37]. The logical response 
to this was to introduce therapies which increase cardiac 
output, with the aim to overcome relative hypoperfusion 
and therefore improve patients’ outcomes [35–37]. This 
theory of pathogenesis of organ dysfunction and death in 
sepsis has been the dominant paradigm since its incep-
tion in 1960s [38, 39]. However, evidence is accumulat-
ing, suggesting this paradigm may be fundamentally 
incorrect.
Changing understanding of sepsis 
and resuscitation
The case for tissue hypoperfusion in hyperdynamic sep-
sis was based on the occurrence of an increased lactate, 
oliguria and delivery-dependent oxygen consumption, 
with each finding attributed to occur due to inadequate 
blood flow. It was then assumed that fluid resuscitation 
would produce clinically relevant improvements in car-
diac output able to reverse pathological tissue hypoperfu-
sion. This example of linear clinical reasoning based on 
physiology is likely to be overly simplistic, and each ele-
ment can be challenged by current evidence.
Increased lactate in sepsis
Tissue hypoperfusion leading to tissue hypoxia was 
thought to be the dominant mechanism accounting for 
the increased lactate seen in sepsis [37, 40, 41]. This the-
ory has been challenged by the following observations. 
Direct tissue oximetry in hyperdynamic sepsis failed to 
show tissue hypoxia. Instead, skeletal muscle partial pres-
sure of oxygen in patients with sepsis was found to be 
elevated [42, 43]. Similarly, experimental animal models 
attempting to demonstrate impaired cellular oxidative 
bioenergetics or abnormal lactate/pyruvate ratios have 
not demonstrated evidence of critically impaired oxida-
tive metabolism during sepsis [44–47]. More recently, an 
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alternative mechanism has been proposed to explain the 
increased lactate of sepsis. Aerobic production mediated 
by increased Na/KATPase activity has been demonstrated 
to be a significant contributor to the lactate of sepsis in 
both human and animal models [44, 48]. Microdialysis 
measurements in septic patients showed that skeletal 
muscle lactate was significantly higher than blood lactate 
levels, indicating that there is net contribution of lactate 
to the circulation by skeletal muscle, despite an increased 
skeletal muscle partial pressure of oxygen [42, 43, 48]. 
This theory was supported by the observation that fur-
ther lactate production could be abolished and the gradi-
ent eliminated by locally inhibiting Na/KATPase [48].
The production and clearance of lactate during sepsis 
is a complex, nonlinear and still poorly understood pro-
cess. The current evidence suggests that elevated blood 
lactate level during sepsis is not a reliable indicator of tis-
sue hypoxia [49].
Oliguria in sepsis
Oliguria in patients with sepsis is widely regarded as a 
surrogate for renal tissue hypoperfusion and often used 
as a trigger for fluid resuscitation. There is, however, lit-
tle direct clinical evidence of renal hypoperfusion dur-
ing sepsis. While the available clinical observational 
data are limited in both size and quality, where accu-
rate estimates of renal blood flow in sepsis have been 
reported blood flow has been demonstrated to be mark-
edly increased [50]. Experimental models have demon-
strated variable findings with both reduced and increased 
renal plasma flow reported. It is important to point out 
that many animal models produce hypodynamic sepsis, 
which may explain some of this variation. In models of 
hyperdynamic sepsis, which more accurately mimic the 
clinical syndrome of human septic shock, increased renal 
blood flow has been demonstrated [50]. For example, 
in an ovine model of hyperdynamic septic shock, oligu-
ria occurred despite dramatic increases in both cardiac 
output and renal artery blood flow [51]. These observa-
tions strongly suggest that oliguria is not a function of 
decreased renal perfusion during sepsis.
More importantly, clinical studies both in sepsis and 
in other conditions such as burns have shown that fluid 
resuscitation based on oliguria often has minimal to no 
effect on urine output and fails to reduce renal dysfunc-
tion [52–56].
Delivery‑dependent oxygen consumption
The observation that oxygen consumption can be 
increased by increasing oxygen delivery in patients with 
sepsis is often referred to as “delivery-dependent oxy-
gen consumption” [37, 41]. Its presence has been used to 
infer reversible tissue hypoperfusion and tissue hypoxia 
in hyperdynamic sepsis [41]. However, the observed 
increase in oxygen consumption with increased oxygen 
delivery may be entirely accounted for by coupled effects, 
such as increased myocardial oxygen consumption and 
forced increases in renal oxygen consumption, rather 
than reversal of hypoxia [44]. Secondly, delivery-depend-
ent oxygen consumption has also been observed in the 
setting of chronically ill patients operating at their base-
line. This indicates that the presence of delivery-depend-
ent oxygen consumption may not necessarily indicate 
critical tissue hypoxia [44, 57]. As Dantzker et  al. [58] 
observed (it) “may represent the normal physiological 
behaviour of the system rather than an abnormal mani-
festation of oxygen extraction”.
Effectiveness of resuscitation therapies on achieving 
haemodynamic targets
Fluid resuscitation exerts its potentially therapeutic 
effect by increasing the stressed volume of the circulation 
leading to increased venous return and cardiac output 
[59]. Recently, attempts have been made to quantify the 
potency of fluid administration to achieve this in sepsis. 
Studies in healthy individuals show increases in blood 
volume of 25–30% immediately after administration with 
10–15% persisting 4  h after the infusion [60]. However, 
sepsis is known to produce changes in vascular perme-
ability and the glycocalyx structure that may decrease the 
retention of fluids in the vascular compartment [59]. In 
an animal model of sepsis and fluid bolus resuscitation, 
only 0.6% of the fluid bolus remained in the circulation 
after 20  min [61]. Similar results have been demon-
strated in humans with sepsis, with rapid redistribution 
of a fluid bolus out of the vascular compartment [62–64]. 
Clinically this translates into very small and short-lived 
effects of fluid bolus therapy on haemodynamic param-
eters such as blood pressure, heart rate, cardiac output 
and urine output [52, 65]. An improved understanding of 
the physiological effects of fluid administration has led to 
the development of a revised Starling equation. This new 
model of transvascular fluid exchange is based on recent 
research and considers the contributions of the endothe-
lial glycocalyx layer, the endothelial basement membrane 
and the extracellular matrix [66].
The effect of vasopressors, increasing the stressed 
volume in the venous circulation, has been relatively 
overlooked until recently. In patients admitted to inten-
sive care with septic shock, temporary reductions in 
noradrenaline infusion dose produced corresponding 
reductions in mean systemic filling pressure and car-
diac output [67]. This supports previous observations of 
increased cardiac output and preload with vasopressor 
use in patients with septic shock [68, 69]. Interestingly, in 
a recently published PRCT, the addition of levosimendan 
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to augment cardiac output in patients with sepsis failed 
to show improvements in clinically relevant outcome 
parameters [70]. In another study comparing the early 
use of vasopressin and norepinephrine with or without 
hydrocortisone, similar clinical outcomes were demon-
strated across groups demonstrating a range of possible 
therapeutic approaches to the haemodynamic manage-
ment of sepsis [71].
These studies highlight that interventions other than 
fluid resuscitation could be applied to manipulate 
haemodynamic variables such as cardiac output in sepsis. 
The comparative effectiveness of these therapies remains 
unclear.
Preclinical evidence for the use of fluid 
resuscitation in sepsis
Several experimental studies in animals have investigated 
both the effectiveness of fluid resuscitation in improving 
the septic shock state and its effect on sepsis mortality.
In animal models of septic shock, fluid resuscitation 
resulted in modest improvements in a number of physi-
ological variables. The most consistent finding from 
large animal models of sepsis is that of a short-term 
improvement in cardiac output associated with fluid 
resuscitation, with the effect dissipating rapidly after the 
termination of infusion [72–74]. Similarly, a number of 
studies have demonstrated modest improvements in gas-
trointestinal perfusion with fluid resuscitation [73]; how-
ever, this finding is not consistent in all the animal studies 
[74]. These results support the observation that, although 
gastrointestinal mucosal blood flow is impaired in septic 
shock, treatment strategies specifically aimed at improv-
ing gastrointestinal perfusion such as fluid resuscitation 
have generally failed to correct mucosal perfusion abnor-
malities and failed to show improve important clinical 
endpoints [75].
There are several small and large animal models that 
demonstrate improvements in mortality with fluid resus-
citation. For example, in murine models of both caecal 
ligation and puncture and endotoxemia, fluid resuscita-
tion has consistently been shown to improve mortality 
when compared to no treatment and to provide additive 
benefit to both antibiotics and corticosteroids [76–79]. 
Similarly, fluid resuscitation improved mortality in por-
cine and canine models of endotoxemia and peritonitis, 
respectively [80, 81].
The key problem with these animal studies, as briefly 
mentioned earlier, is the paucity of models that mirror the 
clinical presentation of sepsis in humans. The response to 
both sepsis and endotoxaemia in humans is different to 
commonly used murine, ovine and porcine models [82]. 
The dominant clinical form of sepsis in humans appears 
to be hyperdynamic sepsis, characterised by increased 
cardiac output and decreased systemic vascular resist-
ance (SVR) [9, 32, 33, 35]. When challenged with intra-
venous endotoxin, humans also develop a hyperdynamic 
circulation [34]. This contrasts with the response seen 
in most large and small animal models, where hypody-
namic shock after sepsis or endotoxemia predominates 
[72–74, 76–78, 82, 83]. These disparities occur from both 
the design characteristics of the models and the differ-
ences in human and experimental animal physiology. 
For example, both pigs and sheep have large numbers of 
pulmonary intravascular macrophages that are sensitive 
to circulating endotoxin. Activation leads to the rapid 
development of pulmonary hypertension and right heart 
dysfunction in ovine and porcine models of both sepsis 
and endotoxemia [82]. A similar clinical presentation of 
hypodynamic shock is seen in most murine models [76–
78]. The dominance of hypodynamic models in the ani-
mal literature makes direct extrapolation of the effects of 
fluid resuscitation to human sepsis particularly problem-
atic. The animal literature supports the conclusion that 
fluid resuscitation is effective for hypodynamic models 
of sepsis; however, it yields little insight on its effect in 
hyperdynamic septic shock.
Clinical evidence for the use of fluid resuscitation 
in sepsis
Despite its widespread use, the clinical evidence sup-
porting fluid resuscitation in sepsis remains conflicted. 
Prior to 2001, its use hinged on physiological justification 
and a long history of use, as there were no randomised 
controlled trials (RCTs) that tested fluid resuscita-
tion as an intervention for septic shock. The landmark 
study of early goal-directed therapy (EGDT) by Rivers 
et  al. and the subsequent single-centre and multicen-
tre follow-up RCTs in China were the first prospective 
studies suggesting benefit of the use of fluids in septic 
shock [84–86]. These studies demonstrated the benefits 
of a multi-intervention approach to the initial manage-
ment of sepsis. Because fluid resuscitation was a central 
therapy of EGDT, these studies have been interpreted as 
strong support for the effectiveness of fluid resuscitation. 
Accordingly, these studies of EGDT are the cited refer-
ences for the surviving sepsis guidelines recommending 
fluid resuscitation as the first haemodynamic interven-
tion for patients in septic shock (1C recommendation—
strong recommendation with low-quality evidence) 
[12]. However, while this body of evidence may sup-
port a multifaceted therapeutic approach that includes 
fluid resuscitation, this does not provide evidence for 
its effectiveness as an independent therapy. Fluid resus-
citation was one of many potentially beneficial interven-
tions that were unevenly distributed between groups, in 
both frequency and timing of use, including antibiotics, 
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vasopressors, corticosteroids and intensity of medical 
care [84–86]. Recently, three large RCTs of EGDT have 
been published [87–89]. In these trials, patients assigned 
to EGDT received significantly more fluids than patients 
receiving standard care. EGDT consistently failed to 
show an improvement in mortality for patients with sep-
tic shock, but was associated with more ICU admissions 
and increased utilisation of ICU resources [90]. These 
findings do not support the systematic use of EGDT, of 
which more aggressive fluid resuscitation is a compo-
nent, in the management of patients with septic shock.
The observational data on the effects of fluid resusci-
tation in sepsis are conflicting, with studies suggesting 
equivocal, beneficial and negative effects on mortality.
In one study in 2796 patients across 77 intensive care 
units to determine the effectiveness of surviving sepsis 
guidelines recommended therapies, regression model-
ling showed that fluid challenge for hypotension or ele-
vated lactate had no association with outcome (OR 1.01; 
0.73–1.39) [91]. However, several retrospective reviews 
of septic patients, totalling more than 3000 patients, 
did report positive associations between increased early 
resuscitation volumes and improved mortality [92–95]. 
On the other hand, an increasing number of studies link 
fluid overload in septic patients to worse outcomes [96–
99]. A positive fluid balance has been associated with 
increased mortality in sepsis in a number of studies, but 
it remains unclear whether it is a causative factor [6, 100]. 
For example, in a retrospective analysis of the “vasopres-
sin in septic shock trial” (VASST), an inverse relationship 
between mortality and fluid balance within the first 12 h 
was demonstrated [98]. Of great concern were the find-
ings of the “fluid challenges in intensive care” (FENICE) 
study, a large global inception cohort study [101]. This 
study showed that methods to predict fluid responsive-
ness are not used routinely by clinicians when prescribing 
fluid resuscitation, and safety limits for fluid resuscita-
tion are rarely applied. Importantly, there was no statisti-
cally significant difference in the proportion of patients 
who received further fluids after the previous fluid bolus 
between those with a positive, with an uncertain or with 
a negatively judged response to fluids. In other words, 
patients who were proven to be not fluid responsive con-
tinued to receive the same amount of subsequent fluid 
boluses as did fluid responsive patients. This current 
practice undoubtedly increases the risk of fluid overload 
in critically ill patients [102].
Conversely, a conservative fluid strategy may improve 
patient outcomes, as was shown in the “fluids and cath-
eters treatment trial” (FACTT) [103]. In this study, 1000 
patients with acute lung injury were randomised into a 
conservative and a liberal strategy of fluid management 
using explicit protocols, which were applied for seven 
days. Patients in the conservative strategy arm showed 
significantly improved lung function and shorter dura-
tion of mechanical ventilation and intensive care without 
increasing non-pulmonary organ failures.
Considering the dose–effect relationship and side 
effects of fluids, fluid therapy should be regarded like 
other drug therapy with specific indications and tai-
lored recommendations for the timing, type and dose 
of fluid. Based on this, a conceptual model with four 
phases of intravenous fluid therapy was recently pro-
posed, which include resuscitation, optimisation, 
stabilisation and evacuation (ROSE) [104]. Specific 
strategies for fluid minimisation and de-escalation or 
de-resuscitation have been reported [105–107]. For 
example, in a recently published study, in which a pro-
tocol restricting resuscitation fluid was compared with 
standard care after initial resuscitation patients with 
septic shock showed that patient-centred outcomes all 
pointed towards benefit with fluid restriction [108]. The 
concept of de-resuscitation is further strengthened by a 
post hoc analysis of the RENAL study, which showed 
that a negative mean daily fluid balance was consist-
ently associated with improved clinical outcomes [109]. 
A further and more detailed discussion of fluid minimi-
sation, de-escalation or de-resuscitation is outside the 
scope of this review.
To provide a definitive answer to the crucial question 
what the true effect of fluid administration in the resus-
citation phase of human sepsis is, we need high-level 
evidence from RCTs that compare fluid resuscitation 
versus no fluid resuscitation. This approach requires 
clinical equipoise between these two treatment arms, 
and therefore perhaps a shift in the way clinicians con-
sider fluid resuscitation. Currently, the only randomised 
controlled trial of fluid resuscitation in sepsis is the 
“fluid expansion as supportive therapy trial” (FEAST) 
[110]. The investigators randomised 3141 (of a planned 
3600) children with severe sepsis to receive fluid resusci-
tation with either 40 ml/kg of 0.9% saline or 4% albumin 
or no volume resuscitation. The trial was stopped early 
for harm, demonstrating a 40% increase in mortality 
in both the volume resuscitation arms. Much has been 
made with regard to the correct interpretation of these 
findings [111–113]. It has been suggested that the find-
ings are specific to the unique population with a high 
incidence of malaria (57%), severe anaemia <5 g/dl (32%) 
and acidosis (base deficit >8  mmol/l, 51%) with saline 
and albumin causing disease-specific deterioration and 
worsening of both anaemia and acidosis [111, 112]. 
However, the published subgroup analysis does not sup-
port these conclusions with similar point estimates for 
harm independent of prior malaria, baseline haemoglo-
bin and base deficit [110]. Surprisingly, the increase in 
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mortality did not appear to be related to complications 
of fluid overload but rather to delayed cardiovascular 
collapse [114].
Conclusion
Fluid resuscitation is recommended and widely used as 
the first-line resuscitative therapy for all patients pre-
senting with septic shock. This practice seems mainly 
based on historical beliefs and an incomplete or incorrect 
understanding of the pathophysiology of sepsis.
Viewed as a whole, the bench-to-bedside evidence sup-
porting fluid resuscitation as treatment for sepsis remains 
remarkably weak and highly conflicting. In addition, 
the indiscriminate use of fluid resuscitation, specifically 
beyond the initial resuscitation phase, has the potential 
to cause significant harm.
Although absence of evidence does not equal evidence 
of absence, one could argue there is an urgent need for 
better evidence. The research agenda should focus on 
the development of hyperdynamic animal sepsis models 
which more closely mimic human sepsis and on experi-
mental and clinical studies designed to evaluate minimal 
or no fluid strategies in the resuscitation phase of sepsis.
The recent history of intensive care medicine has 
taught us that overly aggressive attempts to “normalise 
physiology”, focusing on numbers, may be harmful. Per-
haps the most important contribution towards improved 
outcomes of intensive care patients has been the removal 
of ineffective and potentially harmful treatments. Until 
proven otherwise, fluid resuscitation for sepsis fits that 
description.
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